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Shortage of oxygen and nutrients in the brain induces the release of glutamate and
ATP that can cause excitotoxicity and contribute to neuronal and glial damage. Our
understanding of the mechanisms of ATP release and toxicity in cerebrovascular
diseases is incomplete. This review aims at summarizing current knowledge about
the participation of key elements in the ATP-mediated deleterious effects in these
pathologies. This includes pannexin-1 hemichannels, calcium homeostasis modulator-1
(CALHM1), purinergic P2X7 receptors, and other intermediaries of CNS injury
downstream of ATP release. Available data together with recent pharmacological
developments in purinergic signaling may constitute a new opportunity to translate
preclinical findings into more effective therapies in cerebrovascular diseases.
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INTRODUCTION
Cerebrovascular diseases (CVDs) are referred to as a group of conditions that eventually lead
to a reduction of blood supply to the brain as a consequence of a blockage (thrombosis or
atherosclerosis), malformation (aneurysm), hemorrhage, or transient ischemia. In all instances, a
decrease in oxygenation and nutrient supply ultimately leads to brain damage. Cerebrovascular
diseases, principally stroke, constitute the second leading cause of death in adults worldwide and
are major contributors to disability and reduced quality of life (Truelsen et al., 2000), so it is
important to know the mechanisms behind this damage to reduce their consequences with the
design and use of therapies against these diseases.
At the cellular level, damaged neurons and glial cells during and after stressful events in CVDs
release glutamate into the extracellular space, which finally induces cytosolic Ca2+ overload and
excitotoxicity (Braun et al., 1998; Jurányi et al., 1999; Melani et al., 2005; Takeuchi et al., 2006; for
reviews, see also Rossi et al., 2007; Yenari et al., 2010). More recently, ATP was also defined as a
potent excitotoxic signal to oligodendrocytes and neurons (Matute et al., 2007; Domercq et al.,
2010; Cisneros-Mejorado et al., 2015b). In addition to ATP being among the molecules that are
released by cell damage, recent evidence suggests that ATP acts as a damage-associated molecular
pattern (DAMP) to initiate the innate immune response, induce pro-inflammation, and contribute
to progressive neurological injury (Braun et al., 2017). Moreover, the massive increase in the
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cytosolic concentration of Ca2+ is due in part to the
overactivation of P2X7 receptors, a nonselective ligand-gated
cation channel expressed at the cell surface of various cell
types and activated by extracellular ATP. In this review, we
summarize the state of the art regarding the P2X7 receptor
role in cerebrovascular damage and its possible use as a
therapeutic target. In addition, we discuss its relationship with
other molecular agents, such as pannexins (Panxs) and calcium-
permeable channels, representing all together a pathological
orchestrated cluster that can contribute to the onset of tissue
damage and its propagation in CVDs.
P2X7 RECEPTORS ARE MAJOR
MEDIATORS OF TISSUE DAMAGE IN
CEREBROVASCULAR DISEASES
Energy deprivation after stroke causes anoxic and irreversible
depolarization. These events subsequently lead to massive
release of excitatory neurotransmitters, including glutamate
and ATP (Braun et al., 1998; Jurányi et al., 1999; Melani et al.,
2005; Rossi et al., 2007), the latter causing neuronal and glial
cell death through P2X7 receptor activation (Matute et al.,
2007; Domercq et al., 2010; Arbeloa et al., 2012). However,
the mechanisms of deleterious ATP release during brain
ischemia are only partially known (Dale and Frenguelli, 2009;
Cisneros-Mejorado et al., 2015b). Thus, during ischemia, the
lack of oxygen causes a reduction in ATP production with an
ensuing failure of plasma membrane ion pumps and loss of
ion concentration homeostasis, all of which can finally lead
to activation of Panx1 and calcium homeostasis modulator-1
(CALHM1) and the subsequent release of ATP (Cisneros-
Mejorado et al., 2015b). These events lead to sustained activation
of P2X7 receptors and pore formation with ensuing further ATP
release that together creates a vicious circle, resulting in enhanced
ATP-mediated excitotoxicity (Cisneros-Mejorado et al., 2015b).
Indeed, pharmacological blockade or gene ablation of P2X7,
Panx1, and CALHM1 results in substantial delayed post-anoxic
depolarization following oxygen-glucose deprivation (OGD)
and reduced brain tissue damage after transient middle cerebral
artery occlusion (MCAO; Cisneros-Mejorado et al., 2015a, 2018;
Figure 1).
In addition to neuronal and oligodendroglial excitotoxicity,
activation of P2X7 receptors triggers the formation of the
inflammasome, a multiprotein complex that mediates the release
of cytokines, such as IL-1β, IL-18, and IL-33 (Giuliani et al.,
2017; Baroja-Mazo et al., 2013), which can expand the initial
ischemic damage.
P2X7 receptors are expressed in neurons and glia (see
Table 1). Neurons express P2X7 receptors (Yu et al., 2008;
Díaz-Hernández et al., 2009; Miras-Portugal et al., 2017; but
see also Illes et al., 2017), and its blockade prevents ATP
excitotoxicity and reduces the damage in models of both
in vivo and in vitro ischemia (Arbeloa et al., 2012; Cisneros-
Mejorado et al., 2015a). Likewise, oligodendrocytes, which
are the major cellular component of white matter in the
CNS, can undergo direct ATP-mediated excitotoxicity via
activation of P2X7 receptors expressed in their membrane
(James and Butt, 2001; Agresti et al., 2005; Matute et al.,
2007; Yu et al., 2008; Domercq et al., 2010). Indeed,
P2X7 receptors mediate ischemic damage to oligodendrocytes
in culture and in optic nerve explants (Domercq et al., 2010).
Moreover, oligodendrocyte precursor cells (OPCs) also express
P2X7 receptors that contribute to periventricular white matter
during perinatal hypoxic-ischemic injury as this condition
is attenuated with selective antagonists of these receptors
(Wang et al., 2009).
On the other hand, microglia express P2X7 receptors (Ferrari
et al., 1996; Collo et al., 1997; Visentin et al., 1999; Sanz and
Di Virgilio, 2000; Hide et al., 2000; Verderio and Matteoli,
2001; Chafke et al., 2002) that can promote their activation
and proliferation (Bianco et al., 2006; Monif et al., 2009). This
can indirectly cause neurotoxicity by stimulating the production
of reactive oxygen species (Bartlett et al., 2013) as well as the
release of pro-inflammatory cytokines (Suzuki et al., 2004; Shieh
et al., 2014). Interestingly, P2X7 receptors in primary adult
human microglia kept in culture modulate key components of
innate immunity (Janks et al., 2018). Finally, P2X7 receptors
are present in astrocytes (Ballerini et al., 1996; Sun et al., 1999;
Panenka et al., 2001; Franke et al., 2001; James and Butt, 2001;
Kukley et al., 2001), whereby they can raise intracellular Ca2+
concentration and ATP release (Suadicani et al., 2006) as well as
contribute to non-vesicular glutamate release (Duan et al., 2003).
Table 1 summarizes the evidence supporting the expression of
P2X7 receptors in neurons and glia.
Together, these data indicate that activation of P2X7 receptors
can activate deleterious signals after ischemia by altering Ca2+
homeostasis and promoting the release of pro-inflammatory
cytokines as well as causing oxidative stress. Accordingly,
P2X7 blockade reduces tissue damage in experimental models
of CVDs. Thus, Brilliant Blue G (BBG), a P2X7 selective
antagonist, attenuates the extent of brain damage following
transient MCAO (Arbeloa et al., 2012; Cisneros-Mejorado
et al., 2015a). Similarly, BBG treatment ameliorates neuronal
apoptosis in an experimental subarachnoid hemorrhage
model (Chen et al., 2013). Moreover, three different
P2X7 antagonists (BBG, A0438079, and OxATP) significantly
increase survival rates and reduce cognitive deficits and
cell death in transient global ischemia-reperfusion injury
(Chu et al., 2012). Notably, P2X7 receptor attenuated
glial activation and inflammatory cytokine overexpression
in the hippocampus (Chu et al., 2012). Table 2 sums
up the protective effects of the inhibition or deletion of
P2X7 described above.
ACTIVATION AND BIOPHYSICAL
PROPERTIES OF P2X7 RECEPTORS IN
NEURONS AND GLIA
P2X7 receptors have two possible states of conductance.
First, low concentrations of agonist (ATP or BzATP) induce
activation of a nonselective monophasic conductance allowing
monovalent (Na+, K+) and divalent (Ca2+) cation influx and
plasma membrane depolarization (North, 2002). In addition,
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FIGURE 1 | Blockade or genetic ablation of P2X7 receptors, pannexin-1 (Panx1), or calcium homeostasis modulator-1 (CALHM1) channels delays ischemic ionic
currents in acute cortical slices. (A) Representative electrophysiological recordings in whole-cell configuration (holding potential at −80 mV), of ischemic
(oxygen-glucose deprivation, OGD) ionic currents in cortical neurons in acute brain slices from wild-type mice as well as from either P2X7, Panx1, or CALHM1 KO
mice in the presence or absence of inhibitors of these channels. (B) Histogram showing the latency of the onset of ischemic ionic currents following OGD in the
absence (Control) or in the presence of P2X7 receptor antagonist Brilliant Blue G (BBG, 50 nM); Panx1 inhibitors mefloquine (MFQ, 100 nM), carbenoxolone (CBX,
100 µM), and probenecid (1 mM); and CALHM1 inhibitor ruthenium red (RuR, 20 µM). Similar increased latency values were observed in neurons from acute slices
obtained from P2X7 receptor, Panx1, and CALHM1 knockout mice (KO-P2X7, KO-Panx1, and KO-CALHM1, respectively). Concomitant blockade of more than one
target (red columns) did not result in further delay of the post-anoxic current. All the data included in this graph was published earlier (Cisneros-Mejorado et al.,
2015a, 2018; *p < 0.05 vs. control).
after prolonged exposure to high agonist concentrations
(exposure to high agonist concentrations >1 mM ATP, >30
µM BzATP) P2X7 receptors can form a large nonselective
pore allowing the passage of organic cations and molecules of
up to 900 Da and the leakage of metabolites, including ATP
(North, 2002; Yan et al., 2010), as shown in astrocytes (see
above; Suadicani et al., 2006) and microglia (Ferrari et al.,
1997). Although it is not clear whether oligodendrocytes
leak ATP by this mechanism, there is evidence showing that
glucocorticoids increase hemichannel activity in these cells in
a P2X7R-dependent manner, suggesting a possible formation
of a nonselective pore in these conditions (Maturana et al.,
2017). Interestingly, P2X7 receptors in cultured cortical neurons
form a large pore only at very high concentrations of BzATP
and following a prolonged (10–40 s) exposure to the agonist
(Cisneros-Mejorado et al., 2015b) although, in astrocytes
in vitro or HEK cells expressing P2X7 receptors, the large pore
formation occurs more readily (Yan et al., 2010). Macropore
formation cannot be due to receptor pore dilation per se
because the single-channel current amplitude and permeation
characteristics remain constant (Riedel et al., 2007; Pippel et al.,
2017; Di Virgilio et al., 2018). Thus, it appears that additional
mechanisms must underlie the opening of the macropore (see
Braun et al., 2017). This suggests that large pore formation in
cultured neurons depends not only on prolonged stimulation
of the P2X7 receptor. Alternatively, a role in ATP release has
also been assigned to membrane channels formed by Panx1,
which are large-pore ion channels with broad expression in
the CNS (MacVicar and Thompson, 2010). Panx1 is permeable
to molecules up to 900 Da and directly mediates ATP release
(Locovei et al., 2007; Iglesias et al., 2009). The mechanisms
by which P2X7 receptors and Panx1 are involved in pore
formation are not well defined. However, the evidence indicates
in astrocytes, for example, that Panx1 channels are activated
after P2X7 receptor stimulation (Iglesias et al., 2009) or on
concomitant membrane depolarization to induce Panx1 opening
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TABLE 1 | P2X7 receptor expression in the central nervous system.
Cell type Preparation Techniques References
Neuron Mouse brain Ca2+ imaging, IHH, Díaz-Hernández et al. (2009)
qPCR, WB Miras-Portugal et al. (2017)
Rat Brain in situ hybridization Yu et al. (2008)
Oligodendrocyte lineage Rat forebrain OPCs in vitro WB, Ca2+ imaging Agresti et al. (2005)
Rat optic nerve OLs in situ Ca2+ imaging James and Butt (2001)
Rat brain OLs qPCR Yu et al. (2008)
Rat and human optic nerve OLs IHH, WB, Ca2+ imaging, electrophysiology Matute et al. (2007); Domercq et al. (2010)
Microglia Rat and mice brain WB, IHH, in situ hybridization Collo et al. (1997)
Rat brain in vitro Ca2+ imaging, electrophysiology Visentin et al. (1999)
Rat brain in vitro Cytokine reléase, fluorimetry Hide et al. (2000)
Rat brain in vitro IHH, fluorimetry Verderio and Matteoli (2001)
Mouse brain in vitro Electrophysiology, fluorimetry Chafke et al. (2002)
Astrocytes Rat brain in vitro Ca2+ imaging Ballerini et al. (1996)
Astrocyte cell line Ca2+ imaging Sun et al. (1999)
Rat brain in vitro IHH, chemokine signaling Panenka et al. (2001)
Rat brain after lesion IHH Franke et al. (2001)
Rat brain IHH Kukley et al. (2001)
Rat optic nerve in situ Ca2+ imaging James and Butt (2001)
Rat spinal cord Ca2+ imaging, ATP release Suadicani et al. (2006)
IHC, immunohistochemistry; OL, oligodendrocyte; OPCs, oligodendrocyte progenitor cells; qPCR, quantitative PCR; WB, western blot.
TABLE 2 | Protective effects of blocking of P2X7 receptors.
Antagonist Model Effects References
Brilliant Blue G OGD, MCAO Decreases infarct size Arbeloa et al. (2012)
Protects from neuronal death Chu et al. (2012)
Relieves neurological symptoms Cisneros-Mejorado et al. (2015a)
in vitro, EAE Promotes oligodendrocyte survival, protects myelin,
ameliorates neurological symptoms
Matute et al. (2007)
OGD in vitro and in situ Promotes oligodendrocyte survival, protects myelin Domercq et al. (2010)
Perinatal hypoxia-ischemia Reduces white matter injury Wang et al. (2009)
experimental subarachnoid
hemorrhage
Ameliorates function and reduces neuronal apoptosis Chen et al. (2013)
A0438079 MCAO Relieves neurological symptoms Chu et al. (2012)
increase survival rates
Attenuate inflammation
OGD in slices and culture reduce postanoxic depolarization Cisneros-Mejorado et al. (2015a)
OxATP MCAO Reduces mortality Chu et al. (2012)
in vitro, EAE Promotes oligodendrocyte survival, Protects myelin,
ameliorates neurological symptoms
Matute et al. (2007)
Nanobodies in vivo glomerulonephritis Ameliorates experimental glomerulonephritis in mice Danquah et al. (2016)
EAE, experimental autoimmune encephalomyelitis; MCAO, transient middle cerebral artery occlusion; OGD, oxygen-glucose deprivation.
as reported earlier (Locovei et al., 2007). Thus, Panx1 can be
activated following Ca2+ influx via P2X7 receptors along or in
conjunction with subsequent Ca2+-induced Ca2+ mobilization
from intracellular stores (North, 2002; Locovei et al., 2006).
These findings suggest that P2X7 receptors and Panx1 act
synergistically, at least in the CNS, because, in other systems,
pore formation after prolonged activation of the P2X7 receptor
does not occur through Panx1 channels (Qu et al., 2011;
Alberto et al., 2013). One of the best characterized aspects
of P2X7 receptor function is its ability to activate indirectly
the NACHT, LRR, and PYD domains containing protein 3
(NLRP3) inflammasome in macrophages, thereby initiating
caspase-1-mediated IL-1β; processing and release and ultimately
inducing macrophage pyroptotic cell death (Chen et al., 2014).
In the brain, exogenous ATP induces NLRP3 inflammasome
activation in astrocytes and microglia along with an increase
in IL-1β production that activates caspase-1 and amplification
of the stress response (Murphy et al., 2012). Consistent
with this idea, stressed glia increases connexin 43 (Cx43)
and Panx1 hemichannel activity in microglia and astrocytes
of adult mice (Orellana et al., 2015). Moreover, exposure
to high levels of glucocorticoids during gestation induces
long-lasting neuroinflammation and activates the inflammasome
in hippocampal oligodendrocytes of mouse offspring (Maturana
et al., 2017). Thus, oligodendrocytes of control pups showed
expression of inflammasome components (NLRP3, ACS,
and caspase-1), and their levels were increased by prenatal
administration of dexamethasone, a synthetic glucocorticoid.
These cells also showed high levels of IL-1β; and TNF-α; in
accordance with activation of the inflammasome. Notably,
oligodendrocytes showed increased levels of the P2X7 receptors
and Panx1, molecules associated with inflammasome activation
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(Maturana et al., 2017). However, it is not known whether
glucocorticoids also modify the activation properties of
the P2X7/Panx1 axis in neurons, a feature that might be
relevant in CVDs.
P2X7 RECEPTORS ARE INVOLVED IN
ISCHEMIC PRE- AND
POST-CONDITIONING EFFECTS
Brief, non-harmful, ischemic preconditioning can confer
tolerance and protection from subsequent cerebrovascular
damage. Thus, preconditioning attenuates damage in models
of cerebral ischemia associated with oxidative stress and
glutamate excitotoxicity (Jachova et al., 2019). Although
the mechanisms of this phenomenon are unclear, recent
data suggest that P2X7 receptors have a role in ischemia
preconditioning as this is ineffective in P2X7 receptor knockout
mice (Hirayama et al., 2015). In turn, after preconditioning,
P2X7 receptors in astrocytes can orchestrate the initiation of
neuroprotective cascades including those mediated by HIF-1α;
Hirayama et al., 2015). Indeed, P2X7 receptor expression itself is
increased in astrocytes and followed by an elevation of hypoxia-
inducible factor (HIF)-1α in these cells after preconditioning
using an MCAO model in mice (Hirayama et al., 2015).
Moreover, inhibiting the astroglial metabolism with fluorocitrate
abolished the induction of ischemic tolerance, which strongly
suggests that astrocytes play an essential role in its inception
(Hirayama et al., 2015).
In addition, hypoxic preconditioning protects cultured
neurons against hypoxic stress via tumor necrosis factor-α;
TNF-α; Jie Liu et al., 2000; Ruscher et al., 1998). Notably, the
release of TNF-α appears to be dependent on the P2X7 receptor
because microglia treated with BzATP in neuron-microglia
cultures leads to significant reduction in glutamate-induced
neuronal cell death, and either TNF-α-converting enzyme
inhibitor or anti-TNF-α IgG readily suppresses this protective
effect (Suzuki et al., 2004). These findings provide evidence that,
as in astrocytes, P2X7 receptors in microglia contribute to brain
ischemic tolerance though different mechanisms.
The above data argues in favor of a dual role of P2X7 receptors
in CVDs with a protective edge during mild ischemia
(preconditioning) and a deleterious excitotoxic role in more
severe ischemia. This duality adds further complexity to the
development of effective therapies to prevent ischemic injury
by promoting, for example, preconditioning with P2X7 receptor
agonists and/or allosteric modulators while having at hand
antagonists as neuroprotectants to limit the extension of the
ischemic core into the penumbra once stroke occurs. To
define the parameters that limit this double-edged behavior of
P2X7 receptors constitutes a major challenge in experimental
ischemia as a previous step for an effective translation into
CVDs patients.
On the other hand, ischemic post-conditioning may be
more amenable and effective for therapeutic use. Thus,
repetitive short periods of OGD alternated with reperfusion
after prolonged OGD attenuates neuronal apoptosis by
increasing Bcl-2 expression while reducing Bax levels and
overexpressing heat-shock protein 70 (HSP70; Zhao et al.,
2014). Intriguingly, proteomic and functional characterization
of the P2X7 receptor signaling complex showed that HSP70
co-immunoprecipitates with P2X7 receptors (Kim et al., 2001).
This finding strongly suggests an interaction between HSP70 and
P2X7 receptors; however, a direct link between P2X7 activity
and post-conditioning neuroprotection is still missing.
THERAPEUTIC POTENTIAL OF
P2X7 RECEPTOR IN CEREBROVASCULAR
DISEASES
All the above evidence suggests that P2X7 receptor activation
or blockade is involved in the onset and propagation of tissue
damage as well as in neuroprotection and neuroinflammation
in CVDs. Therefore, a thorough understanding of the upstream
events leading to P2X7 receptor activation along with subsequent
downstream signaling cascades they trigger will eventually allow
identifying new cellular and molecular targets amenable for the
design of novel drugs to use in clinical studies.
P2X7 receptor agonists may facilitate ischemia
preconditioning by promoting the release of protective factors
and signals in neurons and glia that ultimately attenuate
major damage (Hirayama et al., 2015). Alternatively, specific
P2X7 agonists may enhance the phagocytic capacity of
microglia as shown in a model of phagocytic function in
fresh human monocytes without promoting pore formation,
thus avoiding unwanted side effects, such as excitotoxicity
or enhanced neuroinflammation (Ou et al., 2018). This
novel role of the P2X7 receptor as a scavenger receptor in
microglia/macrophages and possibly in other cells in the CNS
creates new pharmacological possibilities as it is not affected by
potent selective P2X7 receptor antagonists, and its phagocytic
function has features distinct from its pore function (Ou et al.,
2018). Therefore, differential drug targeting both on P2X7 pore
formation and P2X7-mediated phagocytosis has a great potential
as a single or combined treatment in CVDs.
In addition to agonists and antagonists, other P2X7 receptor
ligands may have therapeutic value. This includes positive
allosteric modulators, such as clemastine, an anti-allergy drug,
which binds extracellularly to P2X7 receptors and potentiates
their ATP-sensitivity while it increases the release of IL-1β;
from lipopolysaccharide-primed macrophages, thus modulating
native immune responses (Nörenberg et al., 2011). In turn,
clemastine may also favor myelination of damaged myelin and
the rescue of behavioral changes that occur after stroke (Liu
et al., 2016; Cohen and Tesar, 2017). Likewise, ginsenosides
of the protopanaxdiol series potently activate P2X7 receptors,
leading to an increase of sustained calcium ion influx in mouse
macrophages that may account for their reported immune
modulatory actions in vivo (Helliwell et al., 2015).
Discovering new uses for approved drugs acting at P2X7 may
provide the quickest possible transition from bench to
bedside in CVDs. Thus, A-740003 (N-(1-[(cyanoimino)(5-
quinolinylamino) methyl] amino-2,2-dimethylpropyl)-2-(3,4-
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dimethoxyphenyl)acetamide), a competitive antagonist of
P2X7 receptors, produces significant antinociception in animal
models of neuropathic and inflammatory pain (Honore et al.,
2006) and has been evaluated for neuroinflammation (Janssen
et al., 2014). On the other hand, AZD9056, an adamantane amide
that was discovered through a program designed to identify
potent and selective P2X7 antagonists, provides a significant
inhibition of ATP-induced IL-1β release in monocytes ex
vivo, suggesting that circulating leucocytes were blocked by
P2X7 (Keystone et al., 2012). AZD9056 is well tolerated and
induces statistically significant changes in parameters of clinical
relevance; however, it failed to ameliorate symptoms in patients
with rheumatoid arthritis, an immunologically mediated disease
in which cytokines are key regulatory molecules. Similarly,
high throughput screening of a compound library provided an
attractive lead compound with modest P2X7 receptor antagonist
potency and high selectivity against a panel of receptors and
channels (Duplantier et al., 2011). Multi-parameter optimization
led to a potent P2X7 antagonist, CE-224,535, which was
advanced to clinical studies for the treatment of rheumatoid
arthritis (Duplantier et al., 2011). This compound is currently
under scrutiny for others brain diseases and has therapeutic
potential in CVDs.
Another interesting approach in the development of biologics
targeting P2X7 receptors are antibodies and nanobodies that
antagonize or potentiate gating of P2X7. Their potential
advantages over small-molecule drugs include high specificity,
lower off-target effects, and tunable in vivo half-life (for a recent
review see Koch-Nolte et al., 2019). Therapeutic antibodies are
commonly injected systemically to maximize delivery; however,
they can be also administered as aerosols to treat respiratory
tract and lung diseases (Van Heeke et al., 2017). In addition,
genetic fusion of P2X7-specific biologics to binding modules
may enable targeting of specific cell subsets; besides, directly
modulating P2X7 function, antibodies can also initiate specific
depletion of P2X7-expressing cells (Koch-Nolte et al., 2019).
Furthermore, adeno-associated viral vectors can be used to
express P2X7-specific antibodies in vivo to achieve long-lasting
biological effects and enable modulation of the function of
P2X7-expressing immune cells via encoded transgenic RNA
or proteins (Koch-Nolte et al., 2019). Indeed, functional
antibodies and nanobodies have already shown promising
therapeutic benefit in animal models of sterile inflammation
(Menzel et al., 2018).
CONCLUSIONS
The present review provides an outlook about the role of
P2X7 receptors in CVDs and their dual function as a cationic
channel and as a precursor of large pore formation. It
summarizes a wealth of evidence demonstrating that inhibition
of P2X7 receptors promotes neuron and glia protection against
brain injury and that they can be essential for the release of
cell-supporting factors. At the same time, these receptors are
also relevant to preconditioning and post-conditioning and,
therefore, emerge as possible targets to attenuate tissue damage
in CVDs and modulate neuroinflammation to constrain the
expansion of the core lesion into the penumbra.
FIGURE 2 | Upstream and downstream events of P2X7 receptor activation in brain cells. ATP release through Panx1 or CALHM1 activates P2X7 receptors, which
induces influx of Ca2+. The prolonged stimulation of P2X7 receptors induces pore formation and further ATP release. Brief depolarization during mild cerebrovascular
diseases (CVDs) may promote the release of protective factors, such as hypoxia-inducible factor (HIF)-1, that confer cellular protection against subsequent ischemic
stimuli. In contrast, severe CVDs trigger a sustained P2X7 receptor depolarization and the release of pro-inflammatory cytokines that cause apoptosis or lysis.
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New, groundbreaking research on therapeutic targeting
on P2X7 receptors is constantly being made available. A
notable example is the relatively recent discovery of a
structural basis for subtype-specific inhibition, which provides
novel mechanistic insights to facilitate the development of
P2X7-specific drugs for treating human diseases (Karasawa
and Kawate, 2016). Moreover, new data on the structural and
functional properties, in combination with cell-based functional
studies, suggest that the P2X7 receptor itself constitutes a lipid-
composition-dependent, dye-permeable pore, whose opening is
facilitated by palmitoylated cysteines near the pore-lining helix
(Karasawa et al., 2017).
In summary, P2X7 receptors contribute to neurotransmission
and glia signaling using Ca2+ as a key second messenger
(Figure 2) although the precise mechanisms mediating
their effects in neurons and glial cells are still unclear.
In mild CVDs, P2X7 receptors are involved directly or
indirectly in preconditioning or post-conditioning by
conditions by promoting the release of protective factors,
such as HIF-1 (Hirayama et al., 2015), resulting in a
pro-survival cascade against subsequent harmful events
in neurons and possibly in oligodendrocytes. Finally, in
severe CVDs, P2X7 receptors promote pore formation,
thus allowing the efflux of large molecules including ATP
and Ca2+ influx causing cytosolic Ca2+ overload and
generating a detrimental feedback loop that ultimately
results in neuronal and oligodendroglial death with the
consequent demyelination along with astrocytic and microglial
activation as well as pro-inflammatory cytokine release.
Further work is warranted to elucidate the exact underlying
mechanisms of the P2X7 receptor in the pathophysiology
of CVDs and to shed light on therapies that simultaneously
target multiple cell types and mechanisms of injury in
these diseases.
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